Description: Alector is pioneering immuno-neurology, a novel therapeutic approach to counteract the multiple pathologies that cause degenerative brain disorders by restoring healthy immune function to the brain. Supporting its scientific approach, the Company’s Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success of these product candidates and shorten the development timelines to bring these therapies to patients.
Home Page: www.alector.com
ALEC Technical Analysis
131 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
415 231 5660
Officers
| Name | Title |
|---|---|
| Dr. Tillman Ulf Gerngross Ph.D. | Co-Founder & Chairman |
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director |
| Dr. Sara Kenkare-Mitra Ph.D. | Pres and Head of R&D |
| Mr. Calvin Yu | VP of Fin. |
| Dr. Marc Grasso M.D. | Chief Financial Officer |
| Mr. Peter Heutink Ph.D. | Chief Scientific Officer |
| Michelle Corral | VP of Communications & Investor Relations |
| Ms. Danielle Pasqualone J.D., Ph.D. | Gen. Counsel |
| Erica Jefferson | VP of Communications & Public Affairs |
| Ms. Clare Hunt M.B.A. | Chief People Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 526.3158 |
|---|---|
| Trailing PE: | 13.5167 |
| Price-to-Book MRQ: | 3.0649 |
| Price-to-Sales TTM: | 5.4898 |
| IPO Date: | 2019-02-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 269 |